Biogen Inc (NASDAQ:BIIB)

CAPS Rating: 4 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Results 1 - 20 of 109 : 1 2 3 4 5 6 Next »

Recs

0
Member Avatar 1badbeerad (32.67) Submitted: 8/25/2015 2:49:57 PM : Outperform Start Price: $290.86 BIIB Score: +0.89

So much growth potential and so little time to discuss it.

Recs

0
Member Avatar TMFInnovator (77.19) Submitted: 8/20/2015 9:23:55 AM : Outperform Start Price: $303.87 BIIB Score: +4.07

Upside potential seems to be missing from today's valuation:

http://www.fool.com/investing/general/2015/08/15/3-reasons-why-i-just-bought-biogen-inc-stock.aspx?source=iaasitlnk0000003

Recs

1
Member Avatar manirg (96.29) Submitted: 8/6/2015 12:08:20 PM : Outperform Start Price: $317.82 BIIB Score: -0.23

undervalued

Recs

0
Member Avatar sullyz0r (59.25) Submitted: 7/28/2015 7:36:56 AM : Outperform Start Price: $312.52 BIIB Score: +1.29

We're getting a bit silly here @ 300. Great company, huge presence in important diseases.

Recs

0
Member Avatar InvestForGood (< 20) Submitted: 6/16/2015 11:36:31 PM : Outperform Start Price: $389.35 BIIB Score: -16.61

Smart well run cutting edge and environmentally friendly company

Recs

0
Member Avatar discokinged (90.23) Submitted: 6/16/2015 10:10:46 AM : Outperform Start Price: $385.71 BIIB Score: -16.55

Mike Tubbs, a UK tipster, is keen on Biogen and likes its low price/earnings ratio when so many biotechs are overvalued

Recs

0
Member Avatar ruinas (45.56) Submitted: 6/2/2015 7:30:14 PM : Underperform Start Price: $388.77 BIIB Score: +15.87

Biotech stocks Are overpriced and should drop in price.

Recs

0
Member Avatar stocky5 (40.58) Submitted: 5/8/2015 9:58:27 AM : Outperform Start Price: $394.54 BIIB Score: -17.29

BIIB is buying $5B of its stock, and it is coming off a period of oversold condition. The company missed its quarterly earnings in what appears to be a seasonal pattern (same as 2014). This is a fast grower with a great track record selling at a reasonable price.

Recs

0
Member Avatar peteypab (33.45) Submitted: 4/24/2015 12:36:43 PM : Outperform Start Price: $404.65 BIIB Score: -19.02

crashing today...alzheimers drug might cash in big

Recs

0
Member Avatar CellBlock9 (91.48) Submitted: 3/29/2015 10:28:03 AM : Outperform Start Price: $433.68 BIIB Score: -26.23

mgk, s&p 4 star, 429.87

Recs

0
Member Avatar quinpeung (49.15) Submitted: 3/24/2015 12:55:19 PM : Outperform Start Price: $459.56 BIIB Score: -28.99

Speculative CAPS run-up play

Recs

0
Member Avatar joaquingrech (97.85) Submitted: 3/23/2015 8:49:54 AM : Outperform Start Price: $448.62 BIIB Score: -27.60

they may have something going on with Alzheimer drugs, highly speculative but I like the trials so far

Recs

1
Member Avatar Cturchi44 (< 20) Submitted: 1/21/2015 5:09:13 PM : Outperform Start Price: $364.00 BIIB Score: -14.24

pipeline

Recs

1
Member Avatar Orffy (50.49) Submitted: 11/20/2014 4:17:10 AM : Outperform Start Price: $300.10 BIIB Score: +3.65

Multiple Sclerosis (MS) is a horrible disease that particularly plagues people living in the Northern Hemisphere (especially North America and Northern Europe). MS is a significant problem that will result in a significant reward for those who can solve its complexities. As of now, the disease has no cure, which means that companies with current research into this disease have an edge on discovering any potential cures. This could be worth many billions of dollars in cash flows for the companies that can accomplish this feat. Biogen Idec has proven itself capable of building effective MS drugs that doctors trust and recommend. With their successful track record and great financials, I see no reason to bet against Biogen Idec. Long-term.

Recs

1
Member Avatar RugbyViking13 (89.53) Submitted: 10/22/2014 9:00:16 PM : Outperform Start Price: $314.00 BIIB Score: -5.66

Staggering numbers from this bio tech company

Recs

1
Member Avatar billmans (< 20) Submitted: 10/22/2014 7:44:45 AM : Outperform Start Price: $300.00 BIIB Score: -1.25

Pipeline!

Recs

0
Member Avatar racoveanul (80.64) Submitted: 7/11/2014 10:17:42 AM : Outperform Start Price: $318.14 BIIB Score: -6.01

I expect at least a point a week from this stock, for the next five years.

Recs

0
Member Avatar TMFFlygal (98.98) Submitted: 7/8/2014 6:47:19 PM : Outperform Start Price: $322.62 BIIB Score: -7.14

Cancer drugs and new MS drug

Recs

0
Member Avatar SnowBawl (< 20) Submitted: 5/15/2014 7:57:08 AM : Outperform Start Price: $295.63 BIIB Score: -2.88

4 Big Elderly. Reeves.

Recs

0
Member Avatar km00nster (< 20) Submitted: 5/8/2014 7:59:02 PM : Outperform Start Price: $320.20 BIIB Score: -11.80

BIIB and GILD are my 2 top holdings. In the long term, this is a no brainer. Very stacked pipeline.

Results 1 - 20 of 109 : 1 2 3 4 5 6 Next »

Featured Broker Partners


Advertisement